G0326000
Gliclazide
European Pharmacopoeia (EP) Reference Standard
Sinonimo/i:
1-(3-Azabicyclo[3.3.0]oct-3-yl)-3-p-tolylsulphonylurea
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
About This Item
Formula empirica (notazione di Hill):
C15H21N3O3S
Numero CAS:
Peso molecolare:
323.41
Numero MDL:
Codice UNSPSC:
41116107
ID PubChem:
NACRES:
NA.24
Prodotti consigliati
Grado
pharmaceutical primary standard
Famiglia di API
gliclazide
Produttore/marchio commerciale
EDQM
Punto di fusione
163-169 °C (lit.)
applicazioni
pharmaceutical (small molecule)
Formato
neat
Temperatura di conservazione
2-8°C
Stringa SMILE
Cc1ccc(cc1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2
InChI
1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)
BOVGTQGAOIONJV-UHFFFAOYSA-N
Cerchi prodotti simili? Visita Guida al confronto tra prodotti
Descrizione generale
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Applicazioni
Used in the treatment of non-insulin dependent diabetes mellitus (NIDDM).
Azioni biochim/fisiol
Oxidative modification of low-density lipoprotein (LDL) plays an important role in vascular dysfunction associated with diabetes mellitus. Gliclazide is a second-generation sulfonylurea with free-radical-scavenging activity. Incubation of human aortic smooth muscle cell (HASMC) with native human LDL (100 μg/mL) in the presence of increasing concentrations of gliclazide (1 to 10 μg/mL) resulted in a dose-dependent decrease in HASMC-mediated LDL oxidation. Exposure of HASMCs to gliclazide (1 to 10 μg/mL) and native LDL (100 μg/mL) also led to a dose-dependent decrease in oxidized LDL-induced human monocyte adhesion to HASMCs. In addition, incubation of HASMCs with gliclazide dramatically reduced the ability of oxidized LDL to stimulate the proliferation of these cells. Finally, treatment of HASMCs with gliclazide resulted in a marked decrease in oxidatively modified LDL-induced monocyte chemoattractant protein (MCP)-1 and human heat shock protein 70 (HSP 70) expression, both at the gene and protein levels. These results show that gliclazide, at concentrations in the therapeutic range (5 to 10 μg/mL), is effective in vitro in reducing vascular smooth muscle cell (VSMC) dysfunction induced by oxidatively modified LDL. Administration of gliclazide to type 2 diabetic patients could form part of the strategy for the prevention and management of diabetic cardiovascular diseases
Confezionamento
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Altre note
Sales restrictions may apply.
Prodotti correlati
N° Catalogo
Descrizione
Determinazione del prezzo
Avvertenze
Warning
Indicazioni di pericolo
Consigli di prudenza
Classi di pericolo
Acute Tox. 4 Oral
Codice della classe di stoccaggio
11 - Combustible Solids
Classe di pericolosità dell'acqua (WGK)
WGK 2
Punto d’infiammabilità (°F)
Not applicable
Punto d’infiammabilità (°C)
Not applicable
Choose from one of the most recent versions:
Certificati d'analisi (COA)
Lot/Batch Number
Sorry, we don't have COAs for this product available online at this time.
If you need assistance, please contact Servizio Clienti
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
K G Alberti
Diabete & metabolisme, 20(3 Pt 2), 341-348 (1994-11-01)
Gliclazide is a second-generation sulfonylures that is widely used in the treatment of non-insulin-dependent diabetes mellitus (Type 2 diabetes). It has been recommended for use on the basis of both its metabolic and nonmetabolic effects. It has a clear beneficial
P E Jennings
Journal of diabetes and its complications, 8(4), 226-230 (1994-10-01)
Patients with type II diabetes commonly die from thrombotic vascular disease. Large vessel occlusion due to thrombosis or atherosclerotic stenosis is a process accelerated by diabetes and results in premature death. Diabetic small vessel disease, with its unique microangiopathic process
Guntram Schernthaner
Metabolism: clinical and experimental, 52(8 Suppl 1), 29-34 (2003-08-27)
Gliclazide modified release (MR) is a new formulation of the drug gliclazide and is given once daily. The specifically designed hydrophilic matrix of gliclazide MR leads to a progressive drug release that parallels the 24-hour glycemic profile in type 2
Gábor Winkler
Orvosi hetilap, 155(14), 541-548 (2014-04-01)
In addition to the common blood glucose lowering effect, sulfonylurea compounds are different in many aspects from each other. Based on earlier findings the second generation gliclazide has special advantages within this group. Although the number of experimental and clinical
P E Jennings
Metabolism: clinical and experimental, 49(10 Suppl 2), 17-20 (2000-11-15)
Advanced glycolysation end products (AGEs) and the free radicals generated in this process can both be implicated in the accelerated atherosclerosis and vascular and prothrombotic microangiopathic changes typified by diabetes. The rate of formation of free radicals is dependent on
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.